Literature DB >> 306216

Isoniazid induction of antinuclear antibodies. A prospective study.

N F Rothfield, W F Bierer, J W Garfield.   

Abstract

We prospectively studied 102 patients admitted to the Chest Service with tuberculosis. Four patients (4%) had antinuclear antibodies before therapy and 22 patients (21.6%) developed antinuclear antibodies after treatment. None developed lupus erythematosus cells or signs or symptoms of systemic lupus erythematosus. Age and race were not related to the induction of antinuclear antibodies. The percent of positive sera was similar during and after 3 months of treatment, with higher titers after 3 months of therapy. Although patients were treated with various antituberculosis drugs, isoniazid alone or in combination with other drugs induced antinuclear antibodies.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 306216     DOI: 10.7326/0003-4819-88-5-650

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

Review 1.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

2.  PROLONGED FEVER DURING THE TREATMENT OF PULMONARY TUBERCULOSIS.

Authors:  Deepak Rosha
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review.

Authors:  Fahmi Yousef Khan; Fatima Rasoul
Journal:  Indian J Crit Care Med       Date:  2010-04

Review 4.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

Review 5.  Acetylator phenotype and lupus erythematosus.

Authors:  J P Uetrecht; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 6.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

7.  Systemic lupus erythematosus induced by isoniazid.

Authors:  M Salazar-Páramo; R L Rubin; I García-De La Torre
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

8.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 9.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

10.  Unusual presentation of lupus nephritis.

Authors:  R Gupta; N Gulati; A Gupta; A Kumar; A K Dinda; S K Sharma
Journal:  Rheumatol Int       Date:  2004-10-13       Impact factor: 3.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.